Atopic Dermatitis

A broad look at the ongoing challenges and unmet needs in the field of atopic dermatitis management.

Marc Serota, MD, elucidates the heterogeneity of atopic dermatitis and explains how this can contribute to challenges in treating patients.

Expert panelists share excitement for novel therapies in the pipeline for the management of atopic dermatitis.

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

Potent and moderate topical corticosteroids were likely to be effective than milder options for patients with moderate or severe eczema.

Expert perspectives on the interleukin pathway inhibitors, dupilumab and tralokinumab, and their role in managing atopic dermatitis.

A brief discussion on how the coronavirus 2019 pandemic has impacted the management of patients with atopic dermatitis.

Considerations for managing mild-to-moderate versus moderate-to-severe atopic dermatitis and which therapies are appropriate in each setting.

Shared insight on the systemic treatment armamentarium for atopic dermatitis and how it has evolved in recent years.

Moving on to discuss treatment options for patients with atopic dermatitis, experts reflect on optimal use of topical agents in this setting.

A panel of experts discuss role of guidelines and importance of shared-decision making in managing patients with atopic dermatitis.

Investigators proposed limitations to epoxy chemicals in workplace environments, as a substantial number of patients reacted to the epoxy hardener compounds featured in the study.

Dr. Karan Lal speaks to how he has used Instagram to host a variety of conversations regarding dermatology care and connect with patients who might not always have all the appropriate resources.

Investigators believe these results may aid shared decision-making between clinicians and patients.

Internalized skin bias also appeared to mediate the associations of depression and anxiety related to health-related quality of life.

An analysis of the EUROSTAD study found that the median duration of treatment with the biologic was 14 months.

Geriatric dermatology is an emerging field in the world of skin studies, with complications including cognition, polypharmacy, mobility, social support, and sleep disturbance affecting access to care.

Expert perspectives on assessing quality of life when discussing atopic dermatitis and inflammatory disease with patients.

Shared insight on the nature of inflammation in conjunction with atopic dermatitis with special considerations for possible contributors and severity of disease.

Primary results from these 2 phase 3 trials demonstrated efficacy and safety of the biologic through 16 weeks in patients with atopic dermatitis, but longer-term outcomes remained unknown.

Investigators believe that the prevalence of rosacea familiarity had been underestimated in previous reports.

Patients with eczema who reported comorbid anxiety and depression were more likely to report lower levels of self-management.

Investigators note that the histopathologic diagnosis of inflammatory skin disorders can prove challenging, with psoriasis being particularly heterogeneous and dynamic.